Symbol: CIPLA
Month: 2025-04
Start Price: ₹1444.25
End Price: ₹1550.10
12M Return: 7.33%
6M Return: 7.33%
3M Return: 7.33%
Volatility: 0.342
Sharpe Ratio: 3.065
Max Drawdown: -0.074
Peer Correlation (SUNPHARMA): 0.8178
Peer Correlation (DIVISLAB): 0.6809
Peer Correlation (GRASIM): 0.7009
Average Peer Correlation: 0.7332

Generate a short summary and suggest whether to BUY, SELL, or HOLD.

--- LLM Output ---
**Summary:**

Cipla's stock has performed well over the past year, with a 12-month return of 7.33%. The company's volatility is relatively low at 0.342, and its Sharpe Ratio of 3.065 indicates that the returns have been generated with relatively low risk. The maximum drawdown of -0.074 suggests that the stock has been relatively stable. In terms of peer correlation, Cipla's correlation with its peers is high, particularly with SunPharma, which may indicate that the stock is closely tied to the pharmaceutical industry.

**Recommendation:**

Based on the analysis, I would suggest a **BUY** recommendation for Cipla. The stock's strong returns, low volatility, and high Sharpe Ratio indicate that it has been generating consistent returns with minimal risk. The high correlation with its peers, particularly SunPharma, suggests that the stock is well-positioned to benefit from any positive trends in the pharmaceutical industry. Additionally, the relatively low maximum drawdown suggests that the stock has been relatively stable, which could make it an attractive option for investors seeking steady returns.

However, it's essential to conduct further analysis and consider other factors, such as the company's financials, management team, and industry trends, before making a final investment decision.